Representativeness of Participants Eligible to Be Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries With Alzheimer Disease and Mild Cognitive Impairment

 

From an analysis:

About 90% of people with Alzheimer's disease or mild cognitive impairment had at least one condition -- like cardiovascular disease, prior stroke, blood thinner use, chronic kidney disease, or age over 85 -- that would have excluded them from aducanumab (Aduhelm) clinical trials, an analysis of Medicare data found.

With the possible side effects I will never take something like this.  Hopefully I'm still cognizant enough to object.

Representativeness of Participants Eligible to Be Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries With Alzheimer Disease and Mild Cognitive Impairment

Timothy S. Anderson, MD, MAS¹; John Z. Ayanian, MD, MPP^2,3; Jeffrey Souza, MA⁴; et al Bruce E. Landon, MD, MBA⁴

Author Affiliations

JAMA. Published online September 9, 2021. doi:10.1001/jama.2021.15286

related articles icon

Related

Articles

• Viewpoint
  Evaluation of Aducanumab for Alzheimer Disease
  G. Caleb Alexander, MD, MS; Scott Emerson, MD, PhD; Aaron S. Kesselheim, MD, JD, MPH
• Viewpoint
  FDA on Aducanumab Approval for Alzheimer Disease
  Billy Dunn, MD; Peter Stein, MD; Patrizia Cavazzoni, MD
• Viewpoint
  Will CMS Find Aducanumab Reasonable for Alzheimer Disease?
  Kevin A. Schulman, MD; Michael D. Greicius, MD, MPH; Barak Richman, JD, PhD

t

In June 2021, the US Food and Drug Administration (FDA) granted accelerated approval for aducanumab to treat patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer disease (AD), despite limited evidence of clinical benefit. The 2 phase 3 clinical trials of aducanumab, EMERGE and ENGAGE, were stopped prematurely based on prespecified futility thresholds.¹ Both trials also showed an increased risk of adverse events with aducanumab, including microhemorrhages and vasogenic brain edema, headache, and possibly falls.¹ Though both trials excluded patients based on age, certain chronic diseases, and use of antiplatelet agents and anticoagulants, FDA approval was granted without contraindications or precautions for these unstudied patient populations. We evaluated whether patients enrolled in the trials of aducanumab were representative of patients with dementia enrolled in Medicare by estimating the proportions of Medicare beneficiaries with AD or MCI who would have been excluded from the trials.

Full Text